Kidney recovery functionby KRT: continuous and intermittent KRT · AKI
Subgroup analyses: early showed no clear difference in kidney recovery functionby KRT: continuous and intermittent KRT compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
1 finding from 1 review
Death after 30 days · AKI
Early showed no clear difference in death after 30 days compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
1 finding from 1 review
Death or non recovery kidney function at day 90 · AKI
Early showed no clear difference in death or non‐recovery of kidney function Time frame: day 90 compared with standard initiation of kidney replacement therapy (KRT) (low certainty).
1 finding from 1 review
Recovery of kidney function Patients free from KRT according to ITT analysis (all patients) · AKI
Early showed no clear difference in recovery of kidney function Patients free from KRT according to ITT… compared with standard initiation of kidney replacement therapy (KRT) (low certainty).
1 finding from 1 review
Adverse events: hypophosphataemia · AKI
Early leads to higher adverse events: hypophosphataemia compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Adverse events: hypotension · AKI
Early leads to higher adverse events: hypotension compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Adverse events: cardiac‐rhythm disorder · AKI
Early leads to higher adverse events: cardiac‐rhythm disorder compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Adverse events: infection · AKI
Early showed no clear difference in adverse events: infection compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Duration of ICU stay · AKI
1 finding from 1 review
Need for exchange transfusion · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bilirubin‐induced neurological damage (BIND) · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sudden infant death syndrome · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Treatment failure (annual failure rate) · Children with previously unrestored, vital carious lesions in primary teeth (no pulp therapy); aged 1.5-11 years
Conventional GIC had an annual failure rate of 7.6-16.6% (2 RCTs) and failed more than amalgam in one trial; low quality of evidence (ungraded).
1 finding from 1 review